Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 21 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/1/2002 First Published: 4/1/2002


1.		Phase III Randomized Study of Irofulven Versus Fluorouracil in Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma (Summary Last Modified 06/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				MGI-IROF-003 UARIZ-HSC-00305, NCT00033735

Last Modified: 8/27/2003 First Published: 3/1/2001


2.		Phase I/II Study of Irofulven in Patients With Progressive or Recurrent High-Grade Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, or Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NABTT-2005 JHOC-NABTT-2005, NCT00012038, NABTT-2005


3.		Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				IROF-017 NCT00374660

Last Modified: 5/1/2000 First Published: 8/1/1998


4.		Phase II Study of 6-Hydroxymethylacylfulvene for Advanced Renal Cell Carcinoma (Summary Last Modified 05/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MSKCC-98009 MSKCC-98007, NCI-T97-0119, NCT00003390, T97-0119

Last Modified: 4/1/2000 First Published: 9/1/1998


5.		Phase II Study of 6-Hydroxymethylacylfulvene (MGI-114) for Metastatic Adenocarcinoma of the Colon or Rectum (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MDA-DM-97308 NCI-T97-0113, NCT00003441, T97-0113

Last Modified: 6/14/2006 First Published: 10/1/1998


6.		Phase II Study of 6-Hydroxymethylacylfulvene in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (Summary Last Modified 06/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Not specified				NCI				VU-VCC-THO-9817 NCI-T97-0106, T97-0106

Last Modified: 1/1/2002 First Published: 12/1/1998


7.		Phase II Study of Irofulven in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer (Summary Last Modified 01/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-98-C-0162 MB-403, NCI-T98-0030, NCT00019552, T98-0030

Last Modified: 5/4/2005 First Published: 1/1/1999


8.		Phase II Study of 6-Hydroxymethylacylfulvene in Patients with Relapsed or Refractory Non-Small Cell Lung Cancer (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				CLB-39805 NCT00003666, CALGB-39805

Last Modified: 7/1/2000 First Published: 4/1/1999


9.		Phase II Study of 6-Hydroxymethylacylfulvene (MGI 114) in Patients with Stage III or IV Unresectable Adenocarcinoma of the Pancreas (Summary Last Modified 07/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				UTHSC-9895011082 MGI-114.27.P98-03, SACI-IDD-98-18, NCI-V99-1517, NCT00003760

Last Modified: 4/26/2007 First Published: 4/1/1999


10.		Phase II Study of 6-Hydroxymethylacylfulvine (MGI-114) in Patients with Metastatic Renal Cell Carcinoma (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MDA-DM-98221 NCI-T98-0071, T98-0071

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute